Italia markets closed

Candel Therapeutics, Inc. (CADL)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
6,39-0,04 (-0,62%)
Alla chiusura: 04:00PM EDT
6,56 +0,17 (+2,66%)
Dopo ore: 07:59PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente6,43
Aperto6,59
Denaro6,35 x 400
Lettera6,43 x 400
Min-Max giorno6,02 - 6,60
Intervallo di 52 settimane0,66 - 11,40
Volume386.083
Media Volume5.298.636
Capitalizzazione187,531M
Beta (5 anni mensile)0,92
Rapporto PE (ttm)N/D
EPS (ttm)-1,31
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A11,00
  • GlobeNewswire

    Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting

    One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation in pancreatic cancerTwo preclinical posters characterizing new developments from the enLIGHTEN™ Discovery Platform NEEDHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral

  • GlobeNewswire

    Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer

    Initial data suggests 12-month survival is consistent with an increased tail on the maturing survival curveNegative or low PD-L1 status appears to be associated with long survival in CAN-2409 treated patientsBiomarker data suggests association between immune cell activation and survivalTopline overall survival data expected in Q2 2024 NEEDHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company foc

  • GlobeNewswire

    Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

    NEEDHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023, in New York City. Format: Corporate PresentationD